The millennial-focused digital health company Hims & Hers (HIMS) has donated $1 million to President-elect Donald Trump’s ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

In recent years, more and more celebrities — like Elon Musk and Whoopi Goldberg — have spoken up about using GLP-1 ...

The cult of super skinny is back. But what’s to blame? Weight loss drugs, or the body positivity movement that was supposed ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

Ozempic 3.0? Retatrutide — an experimental drug nicknamed “triple G” — could be your best shot at a slimmer waistline when it ...

Research backs this up: Young men who consumed more protein while losing weight and on an intense exercise regiment gained ...

Ozempic, a weight-loss breakthrough with semaglutide, is revolutionizing fat reduction. Offering faster, more effective ...

Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2025 Preview report featuring updated forecasts for the biopharma market for 2025.

If my belly was a pillow, it would be described as “plush” and “luxurious”. I don’t even think it is unpleasant to look at.

With multiple stakeholders involved with different interests, the “specialty drug” definition can be a moving target.